Regulatory
Twinlab Corporation issues statement in response to FDA warning letter concerning androstenedione
RegulatoryTwinlab Corporation issues statement in response to FDA warning letter concerning androstenedioneTwinlab Corporation issues statement in response to FDA warning letter concerning androstenedione
Twinlab Corporation, a wholly-owned subsidiary of IdeaSphere, Inc. issued a statement in response to the US Food and Drug Administration's warning letter to Twinlab Corporation concerning products containing androstenedione, or "andro."
Subscribe and receive the latest updates on trends, data, events and more.
Join 57,000+ members of the natural products community.